RBM5, a regulator of alternative splicing of apoptotic genes, and its highly homologous RBM6 and RBM10 are RNA-binding proteins frequently deleted or mutated in lung cancer. We report that RBM5/6 and RBM10 antagonistically regulate the proliferative capacity of cancer cells and display distinct positional effects in alternative splicing regulation. We identify the Notch pathway regulator NUMB as a key target of these factors in the control of cell proliferation. NUMB alternative splicing, which is frequently altered in lung cancer, can regulate colony and xenograft tumor formation, and its modulation recapitulates or antagonizes the effects of RBM5, 6, and 10 in cell colony formation. RBM10 mutations identified in lung cancer cells disrupt NUMB splicing regulation to promote cell growth. Our results reveal a key genetic circuit in the control of cancer cell proliferation.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide, 40% of which correspond to nonsmall cell lung adenocarcinomas. RBM5 (also known as LUCA-15/H37), RBM6, and RBM10 are highly similar RNA-binding motif proteins sharing 30%-50% of amino acid sequence identity. RBM5 and RBM6 genes map to chromosomal region 3p21.3, which is frequently deleted in heavy smokers, lung cancer, and other tissue carcinomas (Angeloni, 2007) . RBM5 protein levels are indeed downregulated in $75% of primary lung cancers (Oh et al., 2002) as well as in prostate (Zhao et al., 2012) and in some breast cancer samples (Edamatsu et al., 2000) .Overexpression of RBM5 in breast cancer samples was also reported (Oh et al., 1999; Rintala-Maki et al., 2007) , suggesting that both up-and downregulation of RBM5 could play a role in tumor progression. RBM6 and 10 also show altered expression in breast cancer (Rintala-Maki et al., 2007) . Downregulation of RBM5 is considered one molecular signature associated with metastasis in various solid tumors (Edamatsu et al., 2000; Ramaswamy et al., 2003; Welling et al., 2002) . More recently, RBM10 was found to be among the most frequently mutated genes in lung adenocarcinoma samples (Imielinski et al., 2012) . The frequency of genetic lesions affecting RBM5, 6, and 10 in lung and other cancers suggests that disruption of the function of these proteins can contribute to tumor progression.
Overexpression of RBM5 in various cell lines leads to growth arrest, induction of apoptosis, and retarded tumor growth when cells were injected in nude mice (Mourtada-Maarabouni et al., 2002 Oh et al., 2002 Oh et al., , 2006 . RBM5-mediated apoptosis is associated with upregulation of the proapoptotic protein BAX and downregulation of the antiapoptotic proteins BCL-2 and BCL-XL (Mourtada-Maarabouni et al., 2002; Oh et al., 2006; Sutherland et al., 2001) . Downregulation of RBM5 affects the transcript levels of 35 genes involved in the control of cell proliferation and apoptosis (Mourtada-Maarabouni et al., 2006) , but the key targets of RBM5, 6, and 10 and the regulatory mechanisms behind these properties remain poorly understood.
RBM 5, 6, and 10 contain domains characteristic of proteins with functions in RNA metabolism and pre-mRNA splicing, including two RNA recognition motifs (RRM), two Zinc fingers, bipartite nuclear localization signals, a glycine(G)-patch, one arginine/serine-rich domain, and an OCRE domain (which consists of a repeated sequence of eight residues, organized around a triplet of conserved aromatic amino acids) ( Figure 1A ). Consistent with the presence of diverse RNA-binding domains, a variety of sequences have been identified as bound by these proteins. Thus, in vitro studies showed that RBM5 and 10 specifically bind poly(G) RNA tracts in vitro (Edamatsu et al., 2000) and that the RanBP-ZnF domain of these proteins binds with high affinity to ANGUAA sequences (Nguyen et al., 2011) . On the other hand, the solution structure of the second RRM of RBM5 revealed specific recognition of both CU-rich and GA-rich sequences (Song et al., 2012) . Ex vivo and in vitro data revealed that RBM5 binds to a U/C-rich sequence in the caspase-2 pre-mRNA (Fushimi et al., 2008) and regulates alternative splicing of apoptosisrelated genes (Bonnal et al., 2008; Fushimi et al., 2008) , modulating the production of isoforms with antagonistic functions in programmed cell death. It was also shown that RBM5 targets late events in spliceosome assembly, acting as a switch for splice site pairing in the Fas receptor (CD95/APO-1) pre-mRNA (Bonnal et al., 2008) . It has been reported that RBM5 and 10 are components of prespliceosomal complexes Deckert et al., 2006) .
Alternative splicing of pre-mRNA precursors is a prevalent mode of gene expression regulation in multicellular organisms that involves the interplay between multiple sequence motifs and cognate protein factors that favor or prevent the recognition of splice sites by the splicing machinery (Barash et al., 2010; Chen and Manley, 2009; Wahl et al., 2009 ). Misregulation of alternative splicing contributes to cancer progression by affecting the expression of genes or isoforms involved in cell-proliferation control, apoptosis, DNA-damage response, energy metabolism, angiogenesis, and metastasis (David and Manley, 2010; Kaida et al., 2012) .
In this study, we show that depletion of RBM5, 6, and RBM10 have distinct effects on the ability of cancer cells to proliferate. Using CLIP-Seq and splicing-sensitive microarrays, we identified hundreds of exons, including many implicated in tumor formation and progression, which are bound and/or whose splicing is modulated by one or more of these factors. We found that antagonistic regulation of NUMB alternative splicing by RBM5/6 and RBM10 can largely account for the opposite effects of these factors on cell proliferation, revealing a key circuit of posttranscriptional gene regulation that can be disrupted in cancer cells, as illustrated by the effects of an RBM10 mutant identified in lung adenocarcinoma cells.
RESULTS
Effects of RBM5, 6, and 10 Depletion on Cell Colony Formation HeLa cell lines stably expressing shRNAs against RBM5, 6, or 10 were generated, and the expression levels of those proteins were reduced to 15%, 5%, and 3%, respectively, compared to control cells ( Figures 1B and 1C) . Strikingly, despite the high level of sequence similarity between these proteins, depletion of RBM5 and 6 caused a pronounced decrease in the clonogenic capacity of the cells, whereas depletion of RBM10 resulted in enhanced cell colony formation and noticeably denser colonies ( Figures 1D and 1E) . Equivalent results were obtained with a second set of shRNAs (Figures S1A and S1B). We conclude that RBM5/6 and RBM10 have opposite effects on the capacity of cancer cells to form colonies and proliferate.
Transcriptome-wide Identification of RBM Protein Binding Sites
To identify direct RNA-binding sites and potential target RNAs regulated by RBM proteins, CLIP-Seq experiments were carried out for each of the proteins in replicates as described (Kö nig et al., 2010) . After irradiation of the cells with ultraviolet light, RBM/RNAs complexes were immunoprecipitated with specific antibodies-and complexes between 125-145 KDa, 130-150 KDa, and 140-160 KDa corresponding respectively to RBM5/ RNA, RBM6/RNA, and RBM10/RNA crosslinked species were isolated after fractionation by SDS-polyacrylamide gel electrophoresis ( Figure 1F ). No complexes were detected using a control antibody nor in cells in which the factors were knocked down ( Figures 1F, lanes 1 and 2) . After purification, RNAs were reverse-transcribed, PCR amplified with barcoded primers, and sequenced using Solexa (Illumina) technology. This yielded, respectively, 133.079, 1.614.330, and 1.307.119 clusters of reads uniquely mapped to the genome, excluding repeat elements and excluding clusters overlapping with equivalent positions in the IgG control. Results from biological replicates showed Spearman correlation coefficients of R 2 = 0.54, 0.85, and 0.82 for RBM5, 6, and 10, thus providing a robust set of specific RNA/RBM interactions ( Figure S1C ). Cluster mapping to genic regions showed that RBM binding sites were mainly associated with intronic regions (81%, 76%, and 79% of total clusters for RBM5, 6, and 10, respectively). When normalized to the general distribution of intron/exon lengths in the genome, however, binding sites were significantly enriched in exonic regions ( Figure 1G ). Clusters mapped to a total number of 20,387 protein-coding genes ( Figure S1D ). Gene ontology analysis of the extensive overlap of 9,402 genes using the software GORILLA (Eden et al., 2009) showed enrichment in pathways involved in apoptosis, cell adhesion, actin/cytoskeleton reorganization, and signal transduction ( Figure S1E ). This enrichment is consistent with and expands a previous study identifying 35 genes involved in the control of cell proliferation and apoptosis as targets of RBM5 regulation (Mourtada-Maarabouni et al., 2006) .
To investigate the distribution of RBMs binding sites relative to exon-intron junctions, CLIP clusters were mapped to those boundaries after normalizing by the length of exons and introns. The mapping revealed an enrichment of RBM5 and 6 binding sites in exons, mostly within 50 nucleotides of the 3 0 or 5 0 splice sites, with more pronounced peaks near the 5 0 splice site (Figure 2A , top and middle panels). While RBM10 also showed exonic binding sites near the 5 0 splice sites, two other prominent peaks were detected within the 100 nucleotides region 5 0 of the 3 0 splice sites and 3 0 of the 5 0 splice sites ( Figure 2A , lower panel).
When reads were separately mapped to strong and weak splice sites, a clear enrichment of exonic binding sites near weak 5 0 splice sites compared to strong 5 0 splice sites was detected ( Figure 2B ). These results suggest that RBM proteins are general contributors to the splicing process but can particularly contribute to the modulation of exons harboring weak 5 0 splice sites, without a clear enrichment in alternative over constitutive exons ( Figure S2B ).
The distinct distribution of binding sites of RBM proteins could be a consequence of their different RNA sequence specificities. To determine in vivo target sequence motifs of the RBM proteins, enriched 5-mers present in CLIP-Seq clusters were identified. RBM5, 6, and 10 clusters (73.7%, 61.8%, and 62.0%, respectively) included the enriched 5-mers, respectively. The distribution of these motifs recapitulates the general cluster distribution for these proteins ( Figure 2C ), indicating that these motifs are indeed representative of the binding distribution of these factors. Next, consensus motifs were derived using the HOMER software (Heinz et al., 2010) . Two examples of the ten most significantly enriched motifs for each RBM ( Figure S2A ) are shown in Figure 2D . For RBM5, UCAUC and AGUAA sequences were found among the most significantly enriched motifs, which show similarities with the previously published UC-rich RBM5 regulatory motif (Fushimi et al., 2008) as well as with the ANGUAA motif (Nguyen et al., 2011) . RBM10 and 6 showed preference for the CUCUGAA motif, which contains a core CUCU sequence reminiscent of PTB binding sites (Xue et al., 2009) . Additional U-rich motifs were also enriched in RBM10 clusters, consistent with the in vitro observation that RBM10 interacts with poly-U sequences (Inoue et al., 1996) . This analysis therefore allowed us to validate in a genome-wide manner motifs previously described for individual genes and in addition expand the sequence motif repertoires of these RBM proteins. Top consensus motifs were used for electrophoretic mobility retardation assays using N-terminal fragments of RBM5, 6, and 10 comprising the two RRMs and the first zinc finger domains, in the presence of an excess of nonspecific RNA competitor. RBM5 and 6 bound their top consensus motifs with apparent affinities of 50-70 Nm, and for RBM10 the apparent affinity was 150 nM (Figures 2E and S2C) , confirming that these proteins have significant intrinsic binding for the sequences identified in vivo. Using the RNAcompete approach, Ray et al. recently reported preferred sequence motifs for RBM5 and 6 (Ray et al., 2013) . RBM5 and 6 bound to these sequences with an affinity slightly lower than to our CLIP top motifs ( Figures 2E and S2C ). Single-nucleotide substitutions in the CLIP motifs led to 3-to 7-fold decreases in affinity, and binding to unrelated sequences was undetectable ( Figures 2E and S2C ), indicating that RBM5, 6, and 10 display sequence-specific RNA recognition.
Identification of Alternative Splicing Events Regulated by RBMs
To determine the global effects of the three RBMs on the regulation of alternative splicing and also to infer the functional relevance of the identified RBMs/RNA interactions, RNAs isolated from three biological replicas of each of the cell lines expressing shRNAs against the individual RBMs were hybridized to splicingsensitive microarrays. Significant and consistent changes in alternative splicing were detected compared to control cell lines ( Figure S3A ). Depletion of RBM5 affected expression of 281 transcripts, 80% of which were downregulated, whereas depletion of RBM6 and 10 affected expression of a larger set of 1202 and 1294 transcripts, respectively, more than 80% of which were upregulated ( Figure 3A) . Interestingly, the overlap between regulated targets was rather limited ( Figure 3D ), revealing distinct regulatory functions for these highly similar factors. It was previously shown that regulation of RBM5 expression affects the transcript levels of 35 genes involved in the control of cell proliferation and apoptosis (Mourtada-Maarabouni et al., 2006) . Enrichment analysis of KEGG pathways (Kanehisa et al., 2012) in our data revealed, in addition to genes involved in apoptosis and cancer pathways, enrichment in pathways linked to cardiac diseases and hematopoietic cell lineages (RBM5) or to neurodegenerative diseases (RBM10) ( Figure S3B ), suggesting the involvement of the regulatory functions of these factors on a variety of biological processes. The microarray analysis also revealed that depletion of these RBM proteins has substantial effects on alternative splicing, most commonly affecting cassette exons ( Figure 3B ). This observation is consistent with the presence of RBM5 and 10 in spliceosomal complexes and with known functions of RBM5 in Fas and Caspase 2 alternative splicing (see Introduction). Although a role for RBM6 in splicing had not been reported, these data showed a comparable substantial number of alternative splicing events affected by depletion of RBM6 or 10 ( Figures 3B and 3C ). Similar genome-wide analyses comparing the impact of hnRNP proteins on alternative splicing revealed a wide repertoire of events regulated by the six members of this family (Huelga et al., 2012) , while other splicing regulators such as TDP-43 (Tollervey et al., 2011) , HnRNPU (Xiao et al., 2012) , TIA1/TIAL1 , and MBNL (Du et al., 2010 ) display a more restricted tissue/cell-type-specific spectrum of regulatory activities, mostly on cassette exons, as was the case for RBM proteins ( Figure 3B ). Using stringent criteria, our analysis predicted that depletion of RBM5 and 10 (E) Quantitative RT-PCR validation of RBM-regulated alternative splicing changes affecting cassette exons in genes involved in cell proliferation. Fold changes in skipping, after normalization for gene expression using amplification products corresponding to flanking constitutive exons upon knockdown of RBM5 (blue), 6 (red), and 10 (green) are represented. Average values and standard deviation for three independent biological replicates are shown. The validation rates of microarray predictions in these examples were 80% for RBM5 knockdown and 100% for 6 and 10 knockdown.
induce exon inclusion in 63% and 59% of their target exons, respectively, whereas RBM6 depletion promoted inclusion of only 29% of its target cassette exons ( Figure 3C ). This is again consistent with distinct mechanisms of splicing regulation by these factors and indicates that RBM5 and 10 display mainly repressive activities, consistent with findings for RBM5 in the Fas and Caspase 2 systems (Bonnal et al., 2008; Fushimi et al., 2008) and with a very recent report on RBM10 (Wang et al., 2013) , while RBM6 may act mainly as a splicing activator.
Consistent with this concept, mapping of CLIP clusters to exons showing high or low inclusion levels in HeLa cells (quantified using ENCODE RNA-Seq data) showed an enrichment in RBM6 cluster densities in highly included exons, while RBM5 and 10 showed no significant difference between these categories ( Figure S2B ).
As observed for transcriptional targets, the overlap between alternatively spliced exons regulated by these factors was very limited ( Figure 3D ). However, about 20% of the regulated events are under the control of more than one RBM, suggesting possible synergistic or antagonistic effects of RBM5, 6, and 10 on a subset of their targets. Validation by quantitative RT-PCR of high-or medium-confidence microarray predictions for the three factors was 80%-90%. Figure 3E shows the validation of alternative splicing predictions-after normalizing by gene expression changes-in genes previously shown to be involved in cell proliferation, including oncogenes, apoptotic regulators, MAP kinases, and members of the STAT and NOTCH signal transduction pathways. A regulatory network depicting the effects of RBM proteins on the expression and/or alternative splicing of cancer-related and RNA processing-related genes is shown in Figure S4A .
RNA Maps for RBM5, 6, and 10
Overlap between CLIP and microarray data showed evidence of RBM5 binding in the alternatively spliced genomic region comprising the upstream and downstream introns as well as in the flanking constitutive exons for 50% of the RBM5-regulated exons. The figures reached 93% and 97% for RBM6 and 10, respectively, a statistically highly significant enrichment compared to the occurrence of RBM proteins binding in a random subset of nonregulated exons. While the limited number of RBM5-regulated events prevented us from drawing an RNA map for this factor, RBM6 and 10 displayed distinct patterns of binding relative to their regulated exons and the regulatory outcome of their depletion ( Figure 4A ).
For RBM6, peaks of binding associated with exon skipping were observed close to the constitutive upstream and downstream exons, suggesting that RBM6 promotes exon skipping by enhancing the function of the distal splice sites. Other peaks of binding associated with exon skipping or inclusion are located about 200 nucleotides downstream of the 5 0 exon, perhaps due to repression of regulatory sequences. Peaks more specifically associated with alternative exon inclusion are located within the 100 nucleotide intronic regions flanking the regulated exon.
For RBM10, peaks of binding associated with exon skipping were observed throughout the 5 0 intron and the 3 0 end of the exon, while multiple peaks associated with exon inclusion were observed in the 3 0 intron. The effects of RBM10 binding near the 3 0 end of the exon resembles those of hnRNPA1 and could act by similar mechanisms of 5 0 splice-site repression (Huelga et al., 2012; Martinez-Contreras et al., 2006) . The distribution of repressing and activating RBM10 peaks in the upstream and downstream introns, respectively, has resemblances with the RNA maps observed for other splicing regulatory factors (Licatalosi and Darnell, 2010; Llorian et al., 2010; Yeo et al., 2009) .
We conclude that, despite similarities in their binding specificities (Figure 2D ), RBM6 and 10 display distinct positional effects in splicing regulation ( Figure 4A ). Synergistic/antagonistic effects of RBM6 and 10 depending on the location of their binding sites could however be detected ( Figure S4B) .
To evaluate the validity of these insights, we decided to focus on an alternative event in the gene NUMB, which we found to be regulated by RBM5, 6, and 10 (see below) and that is known to be altered in lung cancer (Misquitta-Ali et al., 2011) . A CLIP cluster for RBM10 was found in the 3 0 splice-site region preceding NUMB alternative exon 9. A modified version of the splicing reporter RG6 minigene (Orengo et al., 2006) was generated replacing a model cassette exon by NUMB exon 9 and 100/50 nucleotides of flanking intronic sequences ( Figure 4B ). This allowed us to minimize the alternatively spliced region of NUMB and thus focus on key potential regulatory elements (see below). Consistent with the results of the RNA Map ( Figure 4A ), overexpression of RBM10 in HeLa cells led to enhanced NUMB exon 9 exon skipping in a cotransfection assay using the RG6-NUMB minigene reporter ( Figure 4C, lanes 1-4) . Consistent with the relevance of RBM10 binding 5 0 of the alternative exon, replacement of the RBM10 binding site by another pyrimidine-rich region lacking consensus RBM10 motifs abolished the effects of RBM10 overexpression ( Figure 4C, lanes 5-8) . These results confirm the repressive function of RBM10 when bound 5 0 of an alternative exon. Consistent with the effects of RBM6 depletion, overexpression of this protein led to increased NUMB exon 9 inclusion ( Figure 4C, lanes 9-12) . In contrast, RBM5 overexpression did not change the NUMB exon 9 skipping/inclusion ratio, presumably because of the lack of RBM5-responsive elements in the minigene ( Figure 4C, lanes 13-15) .
Effects of RBM Proteins on Regulation of the Notch Pathway in Breast and Lung Cancer Cell Lines
To investigate the regulation of alternative splicing by RBM5, 6, and 10 in controlled cellular systems, cell lines derived from normal breast and a breast tumor (MCF10A and MCF7) and from normal fetal lung fibroblasts and a lung adenocarcinoma (IMR9 and A549) were used to evaluate the relative expression levels of RBM proteins and alternative splicing of their target genes. Western blot analyses revealed significantly lower levels of RBM5 and 6 in the cancer cell lines from the two tissues, while the levels of RBM10 were higher in the cancer cell lines ( Figure 5A ).
The changes in RBM protein expression were accompanied by changes in alternative splicing of several genes involved in cell proliferation, which were consistent in the two-cell-lines comparisons ( Figure 5B and 5C ). These alternative splicing events were found to be targets of RBM5, 6, and/or 10 in our microarray analyses ( Figure 3E ) and were also identified as direct targets of at least one of them in our CLIP experiments. The differences in RBM5 and/or 6 expression between cancer and noncancer cell lines shown in Figure 5A can contribute to explain only three out of seven of the observed differences in alternative splicing between the cancer cells, and the increase in RBM10 expression cannot explain any of the observed splicing changes (Table S1 ). In sharp contrast, the majority of the changes in alternative splicing observed upon knockdown of the RBMs that were validated in Figure 3E could help to explain the effects of depletion of these factors on cell proliferation (Table S1 ). Given the recent report of frequent mutations of RBM10 in lung adenocarcinomas (Imielinski et al., 2012) , we considered the possibility that RBM10 was mutated in the A549 cell line. Indeed, sequencing of the RBM10 gene in A549 cells revealed a T-to-A substitution at position 1062 that leads to replacement of valine 354 by glutamic acid, a mutation predicted to be located in alpha-helix 2 of the RRM2 domain ( Figure 5D ).
Next, the effect of this mutation on the activity of RBM10 as a regulator of NUMB exon 9 splicing was tested using the assay described in Figure 4C . While overexpression of wild-type RBM10 increased exon skipping ( Figure 5E , lanes 1-6), titration of the V354E mutant found in A549 cells compromised the effects of the protein despite its higher level of expression and, in fact, resulted in even higher exon inclusion at high levels of RBM10 expression ( Figure 5E, lanes 7-11) . Similar effects were observed in alternative splicing of the endogenous gene and in accumulation of NUMB protein isoforms ( Figure S5F ). These observations indicate that this mutation dramatically disrupts RBM10 function. The reduced activity of the V354E mutant could therefore explain (1) why the patterns of alternative splicing observed in the A549 cell line compared to IMR9 cells are opposite to what was inferred based upon the results of RBM10 knockdown ( Figure 5C ) and (2) why there are significantly lower levels of the NUMB PRR S isoform in A549 cells ( Figure 5C , lower panel). Consistent with this interpretation, overexpression of wild-type RBM10 in A549 cells was sufficient to increase skipping of NUMB exon 9 from endogenous transcripts and induce accumulation of the NUMB PRR S protein isoform ( Figure 5F ).
Furthermore, overexpression of wild-type RBM10 reduced the clonogenic capacity of A549 cells ( Figure 5G ), consistent with the idea that RBM10 mutation contributes to A549 cancer cell proliferation.
NUMB Alternative Splicing and RBM-Mediated Regulation of Cell Proliferation
We decided to focus our efforts on NUMB exon 9 alternative splicing regulation for several reasons. First, this event generates mRNAs with opposite effects in the activation of the NOTCH pathway: while exon 9 skipping generates a repressor of the pathway and of cell proliferation, exon 9 inclusion correlates with reduced NUMB protein levels and activation of the NOTCH pathway (Misquitta-Ali et al., 2011; Westhoff et al., 2009 ). Second, the NOTCH pathway is an important regulator of cell proliferation, particularly in lung adenocarcinomas (Maraver et al., 2012) , and changes in NUMB exon 9 inclusion are among the most frequent tumor-associated alternative splicing changes observed in lung cancer (Misquitta-Ali et al., 2011) . Third, the event was regulated in opposite directions by RBM5/6 and RBM10 ( Figure 5C ) and the direction of the changes is consistent with the distinct effects that knockdown of these factors have in cell proliferation assays ( Figures 1D and 1E ). Fourth, direct binding of RBM10 to this alternatively spliced region of NUMB was detected in our CLIP experiments and plays a role in regulation of NUMB exon 9 alternative splicing ( Figure 4C ). Fifth, differences in NUMB alternative splicing and accumulation of NUMB alternatively spliced protein isoforms between the A549 cancer and noncancerous cell lines correlated with expression of a RBM10 mutant that has reduced capacity to regulate NUMB exon 9 skipping ( Figures 5C and 5E ). Sixth, overexpression of wild-type RBM10 in A549 cells was sufficient to increase skipping of endogenous NUMB exon 9, induce accumulation of the NUMB PRR S protein isoform, and decrease the clonogenic capacity of these cells ( Figures 5F and 5G ). Given these precedents, we decided to explore whether regulation of the NOTCH pathway via NUMB alternative splicing can indeed explain the effects of RBM5, 6, and 10 on cell proliferation. We first tested whether knockdown of RBM5, 6, and 10 influenced the activity of the NOTCH pathway. Figure S5A shows that expression of the NOTCH target genes HEY1 and HEY2 (but not HES1) was affected by depletion of the RBM proteins. To further confirm the involvement of the Notch pathway in the activation of cell proliferation mediated by RBM10 depletion, cells were treated with the small molecule peptidomimetic presenilin inhibitor DFP-AA, which blocks Notch signaling and effectively suppresses the growth of Notch1-transformed lymphoid A) RBM6 and 10 functional RNA Maps were generated adopting the method described by Licatalosi et al. (2008) with minor modifications (see Supplemental Experimental Procedures). The density of normalized cluster reads for each protein (y axis) is represented relative to the position of alternative cassette exons (gray boxes) and flanking exonic (black boxes) and intronic (thin line) sequences (x axis). n indicates the number of exon inclusion/skipping events analyzed, as indicated by the blue and red lines, respectively. The profile of cluster densities associated with exon inclusion or skipping events follows the same color code. The gray dashed line represents the distribution of clusters in a random subset of 1000 nonregulated events. Black boxes represent the constitutive exons surrounding the alternative regulated exon (gray box). cell lines in vitro (Weng et al., 2003) . This treatment was sufficient to suppress colony formation of MCF7 and A549 cell lines as well as RBM10-depleted HeLa cells, whereas control knockdown cells were only slightly affected ( Figure 5G ). To further investigate the involvement of RBM proteins in NUMB alternative splicing regulation and cell proliferation, HeLa cell lines depleted of RBM5, 6, or 10 or A549 cells were transfected with plasmids expressing cDNAs encoding one of the two NUMB protein isoforms, NUMB-PRR S or NUMB-PRR L ,
or empty vector as a control. Expression of NUMB PRR S (the isoform generated upon exon 9 skipping) reduced the number of colonies compared to control transfected cells, an effect common to A549, HeLa, and RBM10-depleted HeLa cells ( Figure 6A ). These results indicate that expression of the NUMB isoform that is reduced upon RBM10 depletion is sufficient to counteract the effect of RBM10 depletion on cell proliferation. Conversely, expression of NUMB-PRR L (the isoform generated upon exon 9 inclusion) overcomes the reduction in colony formation caused by depletion of RBM5 or 6 ( Figure 6A ). These results are consistent with and expand previous studies showing that transient overexpression of NUMB PRR L , but not NUMB-PRR S , promotes cell proliferation via activation of NOTCH targets in A549 cell lines (Misquitta-Ali et al., 2011) . Furthermore, these data argue that the effects on cell proliferation caused by depletion of RBM proteins are, at least to a significant extent, due to altered expression of NUMB isoforms. This conclusion is strengthened by the observation that expression of the NUMB-PRR S isoform did not further reduce colony formation in RBM5/6-depleted cells (which have already a high proportion of this isoform), and that expression of the NUMB-PRR L isoform did not further enhance colony formation in RBM10-depleted cells (which have already a high ratio of PRR L to PRR S ) ( Figure 6A) . Protein overexpression may lead to nonphysiological effects due to an excess of the isoforms. To overcome these issues, modified antisense RNA oligonucleotides (AON) were designed to modulate the relative levels of the isoforms generated from endogenous transcripts. We used oligonucleotides complementary to the 5 0 or the 3 0 splice sites (3 0 SS-AON, 5 0 SS-AON) to promote NUMB exon 9 skipping and oligonucleotides complementary to an intronic splicing silencer (E.G.B., unpublished data) (ISS1-AON, ISS2-AON) to promote exon 9 inclusion. The sequences and annealing sites of those AONs are indicated in Figure 6B . MCF7 and A549 cells were transfected with either a single AON or a combination of two or more AONs and the resulting effects on endogenous NUMB exon 9 splicing were assessed by semiquantitative RT-PCR. The 5 0 SS-AON oligo caused efficient exon skipping, while the ISS2-AON oligo enhanced exon 9 inclusion ( Figure 6C, upper panel) . Intermediate ratios of inclusion/skipping were achieved with mixtures of these two oligos.
The AONs did not affect the patterns of four different alternative splicing events regulated by RBM10 (data not shown). Changes in isoform ratios were also detectable at the protein level (Figure 6C , lower panel): consistent with NUMB exon 9 inclusion inducing hyperubiquitination and destabilization of the NUMB protein, which leads to lower overall levels of NUMB protein in lung adenocarcinoma patient samples (Misquitta-Ali et al., 2011) , and with the protein analyses of Figures 5C and 5F , induction of exon inclusion by the ISS2-AON oligo led to overall reduced levels of NUMB, while induction of exon skipping by the 5 0 SS-AON led to higher total levels of NUMB in A549 cells and in HeLa cells depleted of RBM10 ( Figure 6C, lower panel) .
The switch in NUMB exon 9 splicing was accompanied by a marked alteration of the expression of NOTCH targets ( Figures  S5B-S5D ). To evaluate whether splicing modulation of endogenous transcripts by AONs results in changes in the proliferation capacity of cells, clonogenic assays were carried out in A549 and HeLa cells combining the use of these reagents with knockdown of each of the RBM proteins. Induction of exon 9 skipping by the 5 0 SS-AON oligo caused a strong reduction in the number of colonies compared to a control scrambled AON, counteracting the increase in colonies induced by knockdown of RBM10 ( Figure 6D; lanes 3, 7, 11, 15, and 19) . Therefore, the proliferative effects of RBM10 depletion, which causes increased exon inclusion, can be antagonized by increasing the ratio of inclusion/ skipping in transcripts from the endogenous NUMB gene. Conversely, induction of exon 9 inclusion by the ISS2-AON oligo caused a very significant increase in colony formation, counteracting the decrease in colonies induced by knockdown of either RBM5 or 6 ( Figure 6D; lanes 4, 8, and 12) . Thus, the antiproliferative effects of RBM5/6 depletion, which causes exon skipping, can be antagonized by increasing the ratio of inclusion/skipping in transcripts from the endogenous NUMB gene. It is worth pointing out that the ISS2-AON oligo did not further induce colony formation in RBM10 knockdown cells because RBM10 depletion already led to high ratios of exon 9 inclusion (compare lanes 13, 14, and 16 with 17, 18, and 20) .
To further investigate the effects of the 5 0 SS-AON and ISS2-AON on cell proliferation in vivo, A549 cells were transfected with either of the AONs and injected subcutaneously to CB17SC-M nude mice. Simultaneous left and right injections were performed and four nude mice/group were used. During the first 2 weeks after injection, cells transfected with ISS2-AON formed tumors of bigger volume compared with cells transfected with the control AON ( Figure 6E ). This difference in size was attenuated after 2 weeks of injection, most likely because of titration and/or decay of the AON. In contrast, cells transfected with 5 0 SS-AON formed tumors only after 3 weeks of injection, and these tumors remained smaller compared to the control, even after 5 weeks of injection.
DISCUSSION
Our results show that three highly related RBM proteins have overlapping, but also clearly distinguishable sets of RNA targets and even display antagonistic properties in the regulation of cell proliferation. Collectively, our results indicate that the ratio between isoforms of the Notch regulator NUMB is rate limiting for the proliferation of cancer cells and that the regulatory effects of RBM5, 6, and 10 on cell division can be recapitulated, in large part by their effects on the regulation of NUMB alternative splicing.
RNA Binding by RBM Proteins
The CLIP-Seq experiments revealed that each of the RBMs shows affinity for several sequence motifs, possibly due to the presence of different RNA-binding domains (two RRMs, two zinc fingers) in these proteins. For example, the prevalent AGUAA motif identified for RBM5 resembles the ANGUAA motif found to interact with one of its zinc finger domains in vitro (Nguyen et al., 2011) , while UC-rich motifs identified with high confidence in our analyses are similar to a motif found important for RBM5-mediated alternative splicing regulation of Caspase 2 (Fushimi et al., 2008) and to sequences used for structure determination of RBM5 RRM2 bound to RNA (Song et al., 2012) . The latter study also documented interaction of RBM5 RRM2 with GA-rich sequences, which are also present in several of the top motifs identified by our analyses.
The identity of the enriched motifs and the degree of enrichment are most similar between RBM6 and 10 ( Figure S2 ). These factors, however, often have different effects on alternative splicing of common targets (e.g., Figure 3E ) and distinct regulatory maps ( Figure 4A ). These observations argue that the binding and activity of these factors is likely to be influenced by other proteins as well as by their relative positions in the pre-mRNA ( Figure S4B ).
The distribution of RBM5/6 and RBM10 binding sites relative to exon/intron boundaries is also different (Figure 2) . The enrichment of RBM5/6 in exonic regions resembles that of other splicing factors like SRSF3, SRSF4, and FOX2, opening the possibility that, like SR proteins, RBM5 and RBM6 binding in exonic regions near splice sites helps to recruit splicing components (Ä nkö et al., 2012; Yeo et al., 2009) . Indeed, previous work has documented that RBM5 OCRE domain interacts with components of spliceosomal snRNPs and other splicing factors (Bonnal et al., 2008) , although in this case the interaction was associated with exon repression. In contrast, RBM10 binding to intronic regions near splice sites (Figure 2 ) may regulate alternative splicing by interfering with splice-site recognition, similar to the positional effects that have been proposed for FET family proteins (Hoell et al., 2011) and hnRNP C (Kö nig et al., 2010) . Direct blockage of the splicing factor U2AF, which recognizes the polypyrimidine tracts associated to 3 0 splice sites, is a likely mechanism by which RBM10 promotes skipping of NUMB exon 9 ( Figure 4C ), which has been reported for other regulators, as well (Singh et al., 1995; Valcá rcel et al., 1993) . It is interesting to consider, however, that the mutation identified in RBM10 RRM2 in A549 cells, which abolishes RBM10-mediated NUMB regulation, is unlikelyto affect RNA recognition and may block RBM10 activity by failing to synergize with a corepressor. More generally, the RNA Map of RBM10 resembles that of other splicing factors (Licatalosi and Darnell, 2010; Llorian et al., 2010; Yeo et al., 2009) , with skipping/inclusion correlating with binding 5 0 /3 0 of the alternative exon, respectively.
RBMs and Cell Proliferation
Misregulation of alternative splicing contributes to cancer progression (David and Manley, 2010; Kaida et al., 2012; Pal et al., 2012) , and classical splicing regulators like SRSF1 display strong oncogenic activity (Karni et al., 2007) . Many of the key events and regulatory factors involved in splicing-based decisions impacting on cell growth and cancer progression, however, remain to be discovered. A number of alternative splicing changes regulated by RBM5/6 and RBM10 have the potential to contribute to the antagonistic effects of these factors on cell proliferation (Table S1 ), which is also consistent with the identification of multiple genes involved in apoptosis and cell proliferation as targets of RBM5 (Mourtada-Maarabouni et al., 2006) . This is reminiscent of the effects of other splicing regulators like NOVA or ESRP proteins, which orchestrate multiple splice site switches that can contribute to complex cellular functions, like shaping synaptic connections (Ule et al., 2005) or guiding epithelial-mesenchymal transitions (Warzecha et al., 2010) . Our results, however, also reveal that particular alternative splicing events-in our case, in exon 9 of the NUMB gene-can make a predominant contribution to the cell proliferation phenotype controlled by RBM5, 6, and 10.
The gene NUMB encodes a natural inhibitor of the NOTCH pathway (Pece et al., 2010) , a pathway that is hyperactivated in $40% of all human lung adenocarcinomas and correlates with poor prognosis (Dang et al., 2000; Maraver et al., 2012; Westhoff et al., 2009) . NUMB promotes NOTCH ubiquitination and proteosomal degradation of NOTCH intracellular domain (NICD) and may also control NOTCH levels by modulating its endocytic recycling (McGill et al., 2009; McGill and McGlade, 2003) . Inclusion/skipping of exon 9 leads to protein variants that differ in a proline-rich domain involved in protein-protein interactions, and these isoforms display distinct activities, one promoting cell proliferation while the other promotes cell differentiation (Toriya et al., 2006; Verdi et al., 1999) . Our own results using modified oligonucleotides able to modulate the ratio between NUMB isoforms reveal a key role for NUMB alternative splicing regulation in cancer cell proliferation ( Figure 6 ). Of relevance, increased levels of NUMB exon 9 inclusion are frequent in nonsmall lung cancer tumors, correlating with higher NOTCH activity (Misquitta-Ali et al., 2011) . Inhibition of the NOTCH pathway is emerging as a promising new approach for cancer therapy (Purow, 2012) . In particular, pharmacological inhibition of the g-secretase complex, which prevents proteolytic cleavage of the NOTCH receptor and activation of the pathway, blocks cancer growth in a mouse model of lung adenocarcinomas (Maraver et al., 2012) . It is therefore conceivable that modulation of NUMB alternative splicing (e.g., using modified oligonucleotides like those of Figure 6 ) can have therapeutic effects. Approaches for the modulation of alternative splicing with therapeutic potential based upon detailed knowledge of regulatory mechanisms are indeed emerging, including the use of modified antisense oligonucleotides that promote inclusion of exon 7 in the SMN2 gene, thus restoring SMN function in cells and mouse models of spinal muscular atrophy (Hua et al., 2010 (Hua et al., , 2011 Hua et al., 2011; Hua et al., 2008) .
Our observations become particularly relevant after a recent report of massively parallel genome sequencing of lung adenocarcinomas revealed that RBM10 is statistically recurrently mutated in these tumors (12/183, 7%) (Imielinski et al., 2012) . Together with our results implicating RBM10 in lung cancer cell proliferation and in NUMB alternative splicing regulation, these data suggest that mutations in RBM10 contribute to lung adenocarcinoma progression by causing deregulation of NUMB alternative splicing, as we found to be the case for a mutant version of RBM10 found in the lung cancer cell line A549 and for the rescue of NUMB splicing and decrease in cell proliferation upon expression of wild-type RBM10 in these cells ( Figure 5 ).
Of interest, mutations in RBM10 have been also implicated in cleft palate and TARP syndrome (Gripp et al., 2011; Johnston et al., 2010) . These developmental defects in cell proliferation/ differentiation may be influenced by alterations in the regulation of alternative splicing targets of RBM10, as argued by very recent results showing that an in-frame deletion in RBM10 identified in a TARP syndrome patient reduces the accumulation of the protein in the nucleus, affecting its activity as splicing regulator (Wang et al., 2013) . Conceivably, NUMB and regulation of the NOTCH pathway, which plays key roles in cell-fate determination during the development of multiple tissues, could be among the targets affected by altered RBM10 function in these syndromes.
EXPERIMENTAL PROCEDURES Cell Culture Experiments
Conditions for cell culture, Sh-mediated knockdown antisense 2 0 -O-methyl phosphorothioate oligonucletide, and plasmid transfections are described in the Supplemental Experimental Procedures. Clonogenic assays were performed in triplicate using 2000 cells that were plated in 10 cm cell culture dishes with fresh culture medium, replaced every 3 days. After 15 days, cells were washed with PBS and fixed with 5 ml of methanol for 10 min at room temperature. Cells were stained with 5% Giemsa (Sigma, Aldrich) overnight, washed, dried, and counted. Experiments were performed in triplicates.
In Vivo and In Vitro Protein/RNA Interactions CLIP experiments were performed following the protocol of Licatalosi et al., (2008) with slight modifications, which, together with the detailed computational analyses, can be found in the Supplemental Experimental Procedures. Electrophoretic mobility shift assays were carried out using 10 fmol of radiolabeled probes incubated on ice for 15 min with His-RBM Nter in presence of 200 ng/ml yeast tRNA. Mixtures were then loaded on native 5% polyacrylamide gels, and migration was carried out in 0.5%TBE at 150V for 2 hr, followed by gel drying and Phosphorimager analyses.
RNA and Protein Analyses
RNA from three biological replicates of sh-RBM-infected HeLa cells was purified and analyzed using Affymetrix Human Exon Junction Arrays and validated by RT-qPCR as described in the Supplemental Experimental Procedures.
Protein extraction and immunoblot analysis were performed as previously described (Paronetto et al., 2011) .
Xenograft Tumor Formation A549 cells were transfected with AONs. After 48 hr, 10 6 cells were resuspended in 1 ml of Basement Membrane Matrix, Growth Factor Reduced (GFR) (BD, Biosciences). Cells were inoculated subcutaneously in 6-weekold CB17SC-M nude mice. Tumor formation was followed and weekly measured until 5 weeks after injection. Animal work procedures were approved by an institutional review board.
ACCESSION NUMBERS
Microarray data have been submitted in MIAME-compliant form to GEO database (GSE47431) and can be accessed at http://regulatorygenomics.upf.edu/ Data/RBMs/. 
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